Progenics Pharmaceuticals, Inc. Announces Positive Top-Line Results From Second Pivotal Phase 3 Clinical Trial Of Methylnaltrexone In Opioid-Induced Constipation; All Primary And Secondary Efficacy Endpoints Were Highly Statistically Significant

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced positive top-line results from the second pivotal phase 3 clinical trial of methylnaltrexone (MNTX) for the treatment of opioid-induced constipation in patients with advanced medical illness. MNTX is a peripheral opioid receptor antagonist that is designed to treat rapidly the side effects of opioids without interfering with pain relief. In December 2005, Progenics and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced an alliance to co-develop and co-commercialize MNTX.

Back to news